Search

Your search keyword '"Berg, Aad P."' showing total 287 results
Start Over Author "Berg, Aad P."
287 results on '"Berg, Aad P."'

1. Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial

Author

Stoelinga, Anna E. C., Tushuizen, Maarten E., van den Hout, Wilbert B., Girondo, Mar D. M. Rodriguez, de Vries, Elsemieke S., Levens, Amar D., Moes, Dirk-Jan A. R., Gevers, Tom J. G., van der Meer, Suzanne, Brouwer, Hans T., de Jonge, Hendrik J. M., de Boer, Ynte S., Beuers, Ulrich H. W., van der Meer, Adriaan J., van den Berg, Aad P., Guichelaar, Maureen M. J., Drenth, Joost P. H., and van Hoek, Bart

Published
2024
Full Text
View/download PDF

2. Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapy

Author

van Gerven, N.M., Beuers, U., van Erpecum, K.J., den Ouden, J.W., Bhalla, A., Vrolijk, J.M., Koek, G.H., Guichelaar, M.M.J., van Meyel, J.J.M., Baak, L.C., Klemt-Kropp, M., Verhagen, M.A.M.T., Kuijvenhoven, J.Ph., de Jonge, H.M., Stoelinga, Anna E.C., Biewenga, Maaike, Drenth, Joost P.H., Verhelst, Xavier, van der Meer, Adriaan J.P., de Boer, Ynto S., Bouma, Gerd, de Vries, Elsemieke S., Verdonk, Robert C., van der Berg, Aad P., Brouwer, Johannes T., Vanwolleghem, Thomas, Lammers, Wim, Beuers, Ulrich, Sarasqueta, Arantza Farina, Verheij, Joanne, Roskams, Tania, Crobach, Stijn, Tushuizen, Maarten E., and van Hoek, Bart

Published
2024
Full Text
View/download PDF

3. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis

Author

Snijders, Romée J.A.L.M., Stoelinga, Anna E.C., Gevers, Tom J.G., Pape, Simon, Biewenga, Maaike, Tushuizen, Maarten E., Verdonk, Robert C., de Jonge, Hendrik J.M., Vrolijk, Jan Maarten, Bakker, Sjoerd F., Vanwolleghem, Thomas, de Boer, Ynto S., Baven Pronk, Martine A.M.C., Beuers, Ulrich, van der Meer, Adriaan J., Gerven, Nicole M.F. van, Sijtsma, Marijn G.M., van Eijck, Brechje C., van IJzendoorn, Manon C., van Herwaarden, Margot, van den Brand, Floris F., Korkmaz, Kerem Sebib, van den Berg, Aad P., Guichelaar, Maureen M.J., Levens, Amar D., van Hoek, Bart, and Drenth, Joost P.H.

Published
2024
Full Text
View/download PDF

4. Prolonged hypothermic machine perfusion enables daytime liver transplantation – an IDEAL stage 2 prospective clinical trial

Author

de Meijer, Vincent E., Brüggenwirth, Isabel M.A., Lantinga, Veerle A., Moers, Cyril, Monbaliu, Diethard, Hofker, Sijbrand H., Bottema, Jan, Franke, Hildegaard S., de Boer, Marieke T., van den Boom, Anne Loes, Buis, Carlijn I., Fouraschen, Suomi M.G., Hoogwater, Frederik J.H., Klaase, Joost M., de Kleine, Ruben H.J., Meerdink, Mark, Nijkamp, Maarten W., Porte, Robert J., Rayar, A. Michel, van den Berg, Aad P., Blokzijl, Hans, Cuperus, Frans J.C., van der Heide, Frans, van Vilsteren, Frederike G.I., Abbasova, Ilhama F., Fernhout, Meine H., Meyer, Peter, Muskiet, Ernesto R.R., Reyntjens, Koen M.E.M., Vos, Jaap J., Zeillemaker, Miriam, Haring, Martijn P.D., Lascaris, Bianca, Pamplona, Carol C., Thorne, Adam M., Veenma, Vivianne, van Leeuwen, Otto B., Bodewes, Silke B., Lisman, Ton, Adelmeijer, Jelle, Wiersema-Buist, Janneke, van den Heuvel, Marius, and de Kleine, Ruben H.

Published
2024
Full Text
View/download PDF

7. Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial

Author

Snijders, Romée J. A. L. M., Stoelinga, Anna E. C., Gevers, Tom J. G., Pape, Simon, Biewenga, Maaike, Verdonk, Robert C., de Jonge, Hendrik J. M., Vrolijk, Jan Maarten, Bakker, Sjoerd F., Vanwolleghem, Thomas, de Boer, Ynto S., Pronk, Martine A. M. C. Baven, Beuers, Ulrich H. W., van der Meer, Adriaan J., van Gerven, Nicole M. F., Sijtsma, Marijn G. M., Verwer, Bart J., Gisbertz, Ingrid A. M., Bartelink, Maartje, van den Brand, Floris F., Sebib Korkmaz, Kerem, van den Berg, Aad P., Guichelaar, Maureen M. J., Soufidi, Khalida, Levens, Amar D., van Hoek, Bart, and Drenth, Joost P. H.

Published
2022
Full Text
View/download PDF

9. Prolonged hypothermic machine perfusion enables daytime liver transplantation – an IDEAL stage 2 prospective clinical trial

Author

Brüggenwirth, Isabel M.A., primary, Lantinga, Veerle A., additional, Lascaris, Bianca, additional, Thorne, Adam M., additional, Meerdink, Mark, additional, de Kleine, Ruben H., additional, Blokzijl, Hans, additional, van den Berg, Aad P., additional, Reyntjens, Koen M.E.M., additional, Lisman, Ton, additional, Porte, Robert J., additional, de Meijer, Vincent E., additional, Brüggenwirth, Isabel M.A., additional, Moers, Cyril, additional, Monbaliu, Diethard, additional, Hofker, Sijbrand H., additional, Bottema, Jan, additional, Franke, Hildegaard S., additional, de Boer, Marieke T., additional, van den Boom, Anne Loes, additional, Buis, Carlijn I., additional, Fouraschen, Suomi M.G., additional, Hoogwater, Frederik J.H., additional, Klaase, Joost M., additional, de Kleine, Ruben H.J., additional, Nijkamp, Maarten W., additional, Rayar, A. Michel, additional, Cuperus, Frans J.C., additional, van der Heide, Frans, additional, van Vilsteren, Frederike G.I., additional, Abbasova, Ilhama F., additional, Fernhout, Meine H., additional, Meyer, Peter, additional, Muskiet, Ernesto R.R., additional, Vos, Jaap J., additional, Zeillemaker, Miriam, additional, Haring, Martijn P.D., additional, Pamplona, Carol C., additional, Veenma, Vivianne, additional, van Leeuwen, Otto B., additional, Bodewes, Silke B., additional, Adelmeijer, Jelle, additional, Wiersema-Buist, Janneke, additional, and van den Heuvel, Marius, additional

Published
2024
Full Text
View/download PDF

10. Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study):a study protocol for a phase III, open-label, multicentre, randomised controlled trial

Author

Stoelinga, Anna E.C., Tushuizen, Maarten E., van den Hout, Wilbert B., Girondo, Mar D.M.Rodriguez, de Vries, Elsemieke S., Levens, Amar D., Moes, Dirk Jan A.R., Gevers, Tom J.G., van der Meer, Suzanne, Brouwer, Hans T., de Jonge, Hendrik J.M., de Boer, Ynte S., Beuers, Ulrich H.W., van der Meer, Adriaan J., van den Berg, Aad P., Guichelaar, Maureen M.J., Drenth, Joost P.H., Stoelinga, Anna E.C., Tushuizen, Maarten E., van den Hout, Wilbert B., Girondo, Mar D.M.Rodriguez, de Vries, Elsemieke S., Levens, Amar D., Moes, Dirk Jan A.R., Gevers, Tom J.G., van der Meer, Suzanne, Brouwer, Hans T., de Jonge, Hendrik J.M., de Boer, Ynte S., Beuers, Ulrich H.W., van der Meer, Adriaan J., van den Berg, Aad P., Guichelaar, Maureen M.J., and Drenth, Joost P.H.

Abstract

Background: Autoimmune hepatitis (AIH) is a rare, chronic inflammatory disease of the liver. The treatment goal is reaching complete biochemical response (CR), defined as the normalisation of aspartate and alanine aminotransferases and immunoglobulin gamma. Ongoing AIH activity can lead to fibrosis and (decompensated) cirrhosis. Incomplete biochemical response is the most important risk factor for liver transplantation or liver-related mortality. First-line treatment consists of a combination of azathioprine and prednisolone. If CR is not reached, tacrolimus (TAC) or mycophenolate mofetil (MMF) can be used as second-line therapy. Both products are registered for the prevention of graft rejection in solid organ transplant recipients. The aim of this study is to compare the effectiveness and safety of TAC and MMF as second-line treatment for AIH. Methods: The TAILOR study is a phase IIIB, multicentre, open-label, parallel-group, randomised (1:1) controlled trial performed in large teaching and university hospitals in the Netherlands. We will enrol 86 patients with AIH who have not reached CR after at least 6 months of treatment with first-line therapy. Patients are randomised to TAC (0.07 mg/kg/day initially and adjusted by trough levels) or MMF (max 2000 mg/day), stratified by the presence of cirrhosis at inclusion. The primary endpoint is the difference in the proportion of patients reaching CR after 12 months. Secondary endpoints include the difference in the proportion of patients reaching CR after 6 months, adverse effects, difference in fibrogenesis, quality of life and cost-effectiveness. Discussion: This is the first randomised controlled trial comparing two second-line therapies for AIH. Currently, second-line treatment is based on retrospective cohort studies. The rarity of AIH is the main issue in clinical research for alternative treatment options. The results of this trial can be implemented in existing international clinical guidelines. Trial registra

Published
2024

11. Prolonged hypothermic machine perfusion enables daytime liver transplantation - an IDEAL stage 2 prospective clinical trial

Author

Bruggenwirth, Isabel M. A., Lantinga, Veerle A., Lascaris, Bianca, Thorne, Adam M., Meerdink, Mark, de Kleine, Ruben H., Blokzijl, Hans, van den Berg, Aad P., Reyntjens, Koen M. E. M., Lisman, Ton, Porte, Robert J., de Meijer, Vincent E., Bruggenwirth, Isabel M. A., Lantinga, Veerle A., Lascaris, Bianca, Thorne, Adam M., Meerdink, Mark, de Kleine, Ruben H., Blokzijl, Hans, van den Berg, Aad P., Reyntjens, Koen M. E. M., Lisman, Ton, Porte, Robert J., and de Meijer, Vincent E.

Abstract

Background: Liver transplantation is traditionally performed around the clock to minimize organ ischemic time. However, the prospect of prolonging preservation times holds the potential to streamline logistics and transform liver transplantation into a semi-elective procedure, reducing the need for nighttime surgeries. Dual hypothermic oxygenated machine perfusion (DHOPE) of donor livers for 1–2 h mitigates ischemia-reperfusion injury and improves transplant outcomes. Preclinical studies have shown that DHOPE can safely extend the preservation of donor livers for up to 24 h. Methods: We conducted an IDEAL stage 2 prospective clinical trial comparing prolonged (≥4 h) DHOPE to conventional (1–2 h) DHOPE for brain-dead donor livers, enabling transplantation the following morning. Liver allocation to each group was based on donor hepatectomy end times. The primary safety endpoint was a composite of all serious adverse events (SAE) within 30 days after transplantation. The primary feasibility endpoint was defined as the number of patients assigned and successfully receiving a prolonged DHOPE-perfused liver graft. Trial registration at: WHO International Clinical Trial Registry Platform, number NL8740. Findings: Between November 1, 2020 and July 16, 2022, 24 patients were enrolled. The median preservation time was 14.5 h (interquartile range [IQR], 13.9–15.5) for the prolonged group (n = 12) and 7.9 h (IQR, 7.6–8.6) for the control group (n = 12; p = 0.01). In each group, three patients (25%; 95% CI 3.9–46%, p = 1) experienced a SAE. Markers of ischemia-reperfusion injury and oxidative stress in both perfusate and recipients were consistently low and showed no notable discrepancies between the two groups. All patients assigned to either the prolonged group or control group successfully received a liver graft perfused with either prolonged DHOPE or control DHOPE, respectively. Interpretation: This first-in-human clinical trial demonstrates the safety and feasibility of

Published
2024

18. Health-related Quality of Life and Fatigue in Liver Transplant Recipients Receiving Tacrolimus Versus Sirolimus-based Immunosuppression: Results From a Randomized Trial

Author

Mulder, Midas B., primary, Busschbach, Jan van, additional, van Hoek, Bart, additional, van den Berg, Aad P., additional, Polak, Wojtek G., additional, Alwayn, Ian P.J., additional, de Winter, Brenda de C.M., additional, Verhey-Hart, Elke, additional, Erler, Nicole S., additional, den Hoed, Caroline M., additional, and Metselaar, Herold J., additional

Published
2023
Full Text
View/download PDF

19. Transplantation of High-risk Donor Livers After Ex Situ Resuscitation and Assessment Using Combined Hypo- and Normothermic Machine Perfusion: A Prospective Clinical Trial

Author

van Leeuwen, Otto B., de Vries, Yvonne, Fujiyoshi, Masato, Nijsten, Maarten W. N., Ubbink, Rinse, Pelgrim, Gert Jan, Werner, Maureen J. M., Reyntjens, Koen M. E. M., van den Berg, Aad P., de Boer, Marieke T., de Kleine, Ruben H. J., Lisman, Ton, de Meijer, Vincent E., and Porte, Robert J.

Published
2019
Full Text
View/download PDF

20. Randomized Trial of Ciclosporin with 2-h Monitoring vs. Tacrolimus with Trough Monitoring in Liver Transplantation: DELTA Study

Author

Ruijter, Bastian N., primary, Inderson, Akin, additional, van den Berg, Aad P., additional, Metselaar, Herold J., additional, Dubbeld, Jeroen, additional, Tushuizen, Maarten E., additional, Porte, Robert J., additional, Polak, Wojciech, additional, van der Helm, Danny, additional, van Reeven, Marjolein, additional, Rodriguez-Girondo, Mar, additional, and van Hoek, Bart, additional

Published
2023
Full Text
View/download PDF

21. Randomized Trial of Ciclosporin with 2-h Monitoring vs. Tacrolimus with Trough Monitoring in Liver Transplantation:DELTA Study

Author

Ruijter, Bastian N., Inderson, Akin, van den Berg, Aad P., Metselaar, Herold J., Dubbeld, Jeroen, Tushuizen, Maarten E., Porte, Robert J., Polak, Wojciech, van der Helm, Danny, van Reeven, Marjolein, Rodriguez-Girondo, Mar, van Hoek, Bart, Ruijter, Bastian N., Inderson, Akin, van den Berg, Aad P., Metselaar, Herold J., Dubbeld, Jeroen, Tushuizen, Maarten E., Porte, Robert J., Polak, Wojciech, van der Helm, Danny, van Reeven, Marjolein, Rodriguez-Girondo, Mar, and van Hoek, Bart

Abstract

Background and Aims: Previous trials comparing cyclosporine and tacrolimus after liver transplantation (LT) showed conflicting results. Most used trough monitoring for cyclosporine (C0), leading to less accurate dosing than with 2-h monitoring (C2). Only one larger trial compared C2 with tacrolimus based on trough level (T0) after LT, with similar treated biopsy-proven acute rejection (tBPAR) and graft loss, while a smaller trial had less tBPAR with C2 compared to T0. Therefore, it is still unclear which calcineurin inhibitor is preferred after LT. We aimed to demonstrate superior efficacy (tBPAR), tolerability, and safety of C2 or T0 after first LT. Methods: Patients after first LT were randomized to C2 or T0. tBPAR, patient-and graft survival, safety and tolerability were the main endpoints, with analysis by Fisher test, Kaplan–Meier survival analysis and log-rank test. Results: In intention-to treat analysis 84 patients on C2 and 85 on T0 were included. Cumulative incidence of tBPAR C2 vs. T0 was 17.7% vs. 8.4% at 3 months (p=0.104), and 21.9% vs. 9.7% at 6 and 12 months (p=0.049). One-year cumulative mortality C2 vs. T0 was 15.5% vs. 5.9% (p=0.049) and graft loss 23.8% vs. 9.4% (p=0.015). Serum triglyceride and LDL-cholesterol was lower with T0 than with C2. Incidence of diarrhea in T0 vs, C2 was 64% vs. 31% (p≤0.001), with no other differences in safety and tolerability. Conclusions: In the first year after LT immunosuppression with T0 leads to less tBPAR and better patient-/re-transplant-free survival as compared to C2.

Published
2023

24. Study protocol for a multicenter randomized controlled trial to compare the efficacy of end-ischemic dual hypothermic oxygenated machine perfusion with static cold storage in preventing non-anastomotic biliary strictures after transplantation of liver grafts donated after circulatory death: DHOPE-DCD trial

Author

van Rijn, Rianne, van den Berg, Aad P., Erdmann, Joris I., Heaton, Nigel, van Hoek, Bart, de Jonge, Jeroen, Leuvenink, Henri G. D., Mahesh, Shekar V. K., Mertens, Sarah, Monbaliu, Diethard, Muiesan, Paolo, Perera, M. Thamara P. R., Polak, Wojciech G., Rogiers, Xavier, Troisi, Roberto I., de Vries, Yvonne, and Porte, Robert J.

Published
2019
Full Text
View/download PDF

25. Waitlist mortality of young patients with biliary atresia: Impact of allocation policy and living donor liver transplantation

Author

Esmati, Hedayatullah, primary, van Rosmalen, Marieke, additional, van Rheenen, Patrick F., additional, de Boer, Marieke T., additional, van den Berg, Aad P., additional, van der Doef, Hubert P. J., additional, Rayar, Michel, additional, de Kleine, Ruben H.J., additional, Porte, Robert J., additional, de Meijer, Vincent E., additional, and Verkade, Henkjan J., additional

Published
2023
Full Text
View/download PDF

26. Three-year results of renal function in liver transplant recipients on low-dose sirolimus and tacrolimus: a multicenter, randomized, controlled trial

Author

Mulder, Midas B., primary, van Hoek, Bart, additional, van den Berg, Aad P., additional, Polak, Wojciech G., additional, Alwayn, Ian P.J., additional, de Jong, Koert P., additional, de Winter, Brenda C.M., additional, Verhey-Hart, Elke, additional, Erler, Nicole S., additional, den Hoed, Caroline M., additional, and Metselaar, Herold J., additional

Published
2023
Full Text
View/download PDF

27. Additional file 1 of Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial

Author

Snijders, Romée J. A. L. M., Stoelinga, Anna E. C., Gevers, Tom J. G., Pape, Simon, Biewenga, Maaike, Verdonk, Robert C., de Jonge, Hendrik J. M., Vrolijk, Jan Maarten, Bakker, Sjoerd F., Vanwolleghem, Thomas, de Boer, Ynto S., Pronk, Martine A. M. C. Baven, Beuers, Ulrich H. W., van der Meer, Adriaan J., van Gerven, Nicole M. F., Sijtsma, Marijn G. M., Verwer, Bart J., Gisbertz, Ingrid A. M., Bartelink, Maartje, van den Brand, Floris F., Sebib Korkmaz, Kerem, van den Berg, Aad P., Guichelaar, Maureen M. J., Soufidi, Khalida, Levens, Amar D., van Hoek, Bart, and Drenth, Joost P. H.

Abstract

Additional file 1. Spirit checklist.

Published
2023
Full Text
View/download PDF

32. Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial

Author

Snijders*, Romée, primary, Stoelinga*, Anna EC, additional, Gevers, Tom JG, additional, Pape, Simon, additional, Biewenga, Maaike, additional, Verdonk, Robert C, additional, de Jonge, Hendrik JM, additional, Vrolijk, Jan Maarten, additional, Bakker, Sjoerd F, additional, Vanwolleghem, Thomas, additional, de Boer, Ynto S, additional, Pronk, Martine AMC Baven, additional, Beuers, Ulrich HW, additional, Meer, Adriaan J van der, additional, Gerven, Nicole MF van, additional, Sijtsma, Marijn GM, additional, Verwer, Bart J, additional, Gisbertz, Ingrid AM, additional, Bartelink, Maartje, additional, Brand, Floris F van den, additional, Korkmaz, Kerem Sebib, additional, Berg, Aad P van den, additional, Guichelaar, Maureen MJ, additional, Soufidi, Khalida, additional, Levens, Amar D, additional, Hoek*, Bart van, additional, and Drenth*, Joost PH, additional

Published
2022
Full Text
View/download PDF

34. Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial):study protocol for a randomised controlled trial

Author

Snijders, Romée J.A.L.M., Stoelinga, Anna E.C., Gevers, Tom J.G., Pape, Simon, Biewenga, Maaike, Verdonk, Robert C., de Jonge, Hendrik J.M., Vrolijk, Jan Maarten, Bakker, Sjoerd F., Vanwolleghem, Thomas, de Boer, Ynto S., Pronk, Martine A.M.C.Baven, Beuers, Ulrich H.W., van der Meer, Adriaan J., van Gerven, Nicole M.F., Sijtsma, Marijn G.M., Verwer, Bart J., Gisbertz, Ingrid A.M., Bartelink, Maartje, van den Brand, Floris F., Sebib Korkmaz, Kerem, van den Berg, Aad P., Guichelaar, Maureen M.J., Soufidi, Khalida, Levens, Amar D., van Hoek, Bart, Drenth, Joost P.H., Snijders, Romée J.A.L.M., Stoelinga, Anna E.C., Gevers, Tom J.G., Pape, Simon, Biewenga, Maaike, Verdonk, Robert C., de Jonge, Hendrik J.M., Vrolijk, Jan Maarten, Bakker, Sjoerd F., Vanwolleghem, Thomas, de Boer, Ynto S., Pronk, Martine A.M.C.Baven, Beuers, Ulrich H.W., van der Meer, Adriaan J., van Gerven, Nicole M.F., Sijtsma, Marijn G.M., Verwer, Bart J., Gisbertz, Ingrid A.M., Bartelink, Maartje, van den Brand, Floris F., Sebib Korkmaz, Kerem, van den Berg, Aad P., Guichelaar, Maureen M.J., Soufidi, Khalida, Levens, Amar D., van Hoek, Bart, and Drenth, Joost P.H.

Abstract

Background: Currently, the standard therapy for autoimmune hepatitis (AIH) consists of a combination of prednisolone and azathioprine. However, 15% of patients are intolerant to azathioprine which necessitates cessation of azathioprine or changes in therapy. In addition, not all patients achieve complete biochemical response (CR). Uncontrolled data indicate that mycophenolate mofetil (MMF) can induce CR in a majority of patients. Better understanding of first-line treatment and robust evidence from randomised clinical trials are needed. The aim of this study was to explore the potential benefits of MMF as compared to azathioprine, both combined with prednisolone, as induction therapy in a randomised controlled trial in patients with treatment-naive AIH. Methods: CAMARO is a randomised (1:1), open-label, parallel-group, multicentre superiority trial. All patients with AIH are screened for eligibility. Seventy adult patients with AIH from fourteen centres in the Netherlands and Belgium will be randomised to receive MMF or azathioprine. Both treatment arms will start with prednisolone as induction therapy. The primary outcome is biochemical remission, defined as serum levels of alanine aminotransferase and immunoglobulin G below the upper limit of normal. Secondary outcomes include safety and tolerability of MMF and azathioprine, time to remission, changes in Model For End-Stage Liver Disease (MELD)-score, adverse events, and aspects of quality of life. The study period will last for 24 weeks. Discussion: The CAMARO trial investigates whether treatment with MMF and prednisolone increases the proportion of patients in remission compared with azathioprine and prednisolone as the current standard treatment strategy. In addition, we reflect on the challenges of conducting a randomized trial in rare diseases. Trial registration: EudraCT 2016-001038-91. Prospectively registered on 18 April 2016. Graphical Abstract: [Figure not available: see fulltext.].

Published
2022

35. A multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation

Author

Schlegel, Andrea, primary, van Reeven, Marjolein, additional, Croome, Kristopher, additional, Parente, Alessandro, additional, Dolcet, Annalisa, additional, Widmer, Jeannette, additional, Meurisse, Nicolas, additional, De Carlis, Riccardo, additional, Hessheimer, Amelia, additional, Jochmans, Ina, additional, Mueller, Matteo, additional, van Leeuwen, Otto B., additional, Nair, Amit, additional, Tomiyama, Koji, additional, Sherif, Ahmed, additional, Elsharif, Mohamed, additional, Kron, Philipp, additional, van der Helm, Danny, additional, Borja-Cacho, Daniel, additional, Bohorquez, Humberto, additional, Germanova, Desislava, additional, Dondossola, Daniele, additional, Olivieri, Tiziana, additional, Camagni, Stefania, additional, Gorgen, Andre, additional, Patrono, Damiano, additional, Cescon, Matteo, additional, Croome, Sarah, additional, Panconesi, Rebecca, additional, Carvalho, Mauricio Flores, additional, Ravaioli, Matteo, additional, Caicedo, Juan Carlos, additional, Loss, George, additional, Lucidi, Valerio, additional, Sapisochin, Gonzalo, additional, Romagnoli, Renato, additional, Jassem, Wayel, additional, Colledan, Michele, additional, De Carlis, Luciano, additional, Rossi, Giorgio, additional, Di Benedetto, Fabrizio, additional, Miller, Charles M., additional, van Hoek, Bart, additional, Attia, Magdy, additional, Lodge, Peter, additional, Hernandez-Alejandro, Roberto, additional, Detry, Olivier, additional, Quintini, Cristiano, additional, Oniscu, Gabriel C., additional, Fondevila, Constantino, additional, Malagó, Massimo, additional, Pirenne, Jacques, additional, IJzermans, Jan N.M., additional, Porte, Robert J., additional, Dutkowski, Philipp, additional, Taner, C. Burcin, additional, Heaton, Nigel, additional, Clavien, Pierre-Alain, additional, Polak, Wojciech G., additional, Muiesan, Paolo, additional, Alwayn, Ian P.J., additional, van der Berg, Aad P., additional, Carbonaro, Margherita, additional, Claasen, Marco, additional, Daud, Amna, additional, de Meijer, Vincent E., additional, Metselaar, Herold J., additional, Monbaliu, Diethard, additional, Paolucci, Maite, additional, Vets, Sofie, additional, and Winter, Erin, additional

Published
2022
Full Text
View/download PDF

43. Development and validation of a prognostic score for long-term transplant-free survival in autoimmune hepatitis type 1

Author

Biewenga, Maaike, Verhelst, Xavier P. D. M. J., Baven-Pronk, Martine A. M. C., Putter, Hein, van den Berg, Aad P., van Nieuwkerk, Karin C. M. J., van Buuren, Henk R., Bouma, Gerd, de Boer, Ynte S., Simoen, Cedric, Colle, Isabelle, Schouten, Jeoffrey, Sermon, Filip, van Steenkiste, Christophe, van Vlierberghe, Hans, van der Meer, Adriaan J., Nevens, Frederik, van Hoek, Bart, Drenth, J. P. H., van Gerven, N. M., Beuers, U., van Erpecum, K. J., den Ouden, J. W., Bhalla, A., Brouwer, J. T., Vrolijk, J. M., Koek, G. H., Guichelaar, M. M. J., van der Wouden, E. J., van Meyel, J. J. M., Baak, L. C., Verdonk, R. C., Klemt-Kropp, M., Verhagen, M. A. M. T., Kuijvenhoven, J., de Jonge, H. M., Amsterdam Gastroenterology Endocrinology Metabolism, AII - Inflammatory diseases, Gastroenterology and hepatology, Gastroenterology & Hepatology, Groningen Institute for Organ Transplantation (GIOT), Dutch Autoimmune Hepatitis Study Group, Neurosurgery, ANS - Neurovascular Disorders, Gastroenterology and Hepatology, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
Liver Cirrhosis, Male, Cirrhosis, Time Factors, IMPACT, medicine.medical_treatment, Autoimmune hepatitis, risk stratification, Liver transplantation, Gastroenterology, THERAPY, DISEASE, Cohort Studies, Belgium, AIH, Interquartile range, Risk Factors, Medicine and Health Sciences, Child, CIRRHOSIS, transplant‐free survival, Netherlands, risk, Aged, 80 and over, validation, OUTCOMES, liver transplantation, Hazard ratio, autoimmune liver disease, Middle Aged, Prognosis, prognostic score, Hepatitis, Autoimmune, Oncology, Child, Preschool, Cohort, Disease Progression, Original Article, Female, TRIAL, Life Sciences & Biomedicine, long-term survival, Adult, medicine.medical_specialty, Adolescent, long‐term survival, liver, Risk Assessment, Disease-Free Survival, Decision Support Techniques, Young Adult, stratification, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Humans, Aged, Proportional Hazards Models, Science & Technology, Gastroenterology & Hepatology, autoimmune hepatitis, business.industry, Proportional hazards model, Reproducibility of Results, NATURAL-HISTORY, REMISSION, medicine.disease, mortality, transplant-free survival, Transplantation, Multivariate Analysis, Human medicine, Hepatobiliary, business, transplantation
Abstract

BACKGROUND: No prognostic score is currently available for long-term survival in autoimmune hepatitis (AIH) patients. OBJECTIVE: The aim of this study was to develop and validate such a prognostic score for AIH patients at diagnosis. METHODS: The prognostic score was developed using uni- & multivariate Cox regression in a 4-center Dutch cohort and validated in an independent 6-center Belgian cohort. RESULTS: In the derivation cohort of 396 patients 19 liver transplantations (LTs) and 51 deaths occurred (median follow-up 118 months; interquartile range 60-202 months). In multivariate analysis age (hazard ratio [HR] 1.045; p

Published
2021

46. Hypothermic Machine Perfusion in Liver Transplantation — A Randomized Trial

Author

van Rijn, Rianne, primary, Schurink, Ivo J., additional, de Vries, Yvonne, additional, van den Berg, Aad P., additional, Cortes Cerisuelo, Miriam, additional, Darwish Murad, Sarwa, additional, Erdmann, Joris I., additional, Gilbo, Nicholas, additional, de Haas, Robbert J., additional, Heaton, Nigel, additional, van Hoek, Bart, additional, Huurman, Volkert A.L., additional, Jochmans, Ina, additional, van Leeuwen, Otto B., additional, de Meijer, Vincent E., additional, Monbaliu, Diethard, additional, Polak, Wojciech G., additional, Slangen, Jules J.G., additional, Troisi, Roberto I., additional, Vanlander, Aude, additional, de Jonge, Jeroen, additional, and Porte, Robert J., additional

Published
2021
Full Text
View/download PDF

47. Controlled DCD Liver Transplantation Is Not Associated With Increased Hyperfibrinolysis and Blood Loss After Graft Reperfusion

Author

Karangwa, Shanice A., primary, Adelmeijer, Jelle, additional, Burgerhof, Johannes G.M., additional, Lisman, Ton, additional, de Meijer, Vincent E., additional, de Kleine, Ruben H., additional, Reyntjens, Koen M.E.M., additional, van den Berg, Aad P., additional, Porte, Robert J., additional, and de Boer, Marieke T., additional

Published
2021
Full Text
View/download PDF

49. Donor diabetes mellitus is a risk factor for diminished outcome after liver transplantation: a nationwide retrospective cohort study

Author

Brüggenwirth, Isabel M.A., primary, Reeven, Marjolein, additional, Vasiliauskaitė, Indrė, additional, Helm, Danny, additional, Hoek, Bart, additional, Schaapherder, Alexander F., additional, Alwayn, Ian P.J., additional, Berg, Aad P., additional, Meijer, Vincent E., additional, Darwish Murad, Sarwa, additional, Polak, Wojciech G., additional, and Porte, Robert J., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results